Pfizer says Phase 3 SigVie-002 trial misses overall survival endpoint for sigvotatug vedotin in metastatic NSCLC

Pfizer Inc.

PFE

0.00

Pfizer reported topline Phase 3 results for sigvotatug vedotin in previously treated metastatic non-squamous NSCLC.
The study missed its primary overall survival endpoint versus docetaxel in the overall population.
Second-line patients showed a stronger efficacy trend versus docetaxel, supporting continued development in earlier treatment settings.
Safety was manageable and consistent with prior studies; exploratory work did not show a clear expression-response relationship.
Full results have not been presented yet; Pfizer plans to submit them for a future medical congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606221630BIZWIRE_USPR_____20260621_BW867740) on June 22, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.